CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan
Author: Ken Dropiewski
Merit Medical to Participate in Upcoming Investors Conferences in September
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences: The Wells Fargo 2026 Healthcare Conference, which is being held in Boston, MA from September 8-10, 2026. Management is scheduled to participate in a fireside chat on Thursday, September 10th at 8:45 a.m. Eastern Time. The Baird 2026 Global Healthcare Conference, which is being held in New York, NY on September 15, 2026. Management is scheduled to present on Tuesday, September 15th at 8:30 a.m. Eastern Time. The 19th Annual Barrington Research Virtual Fall Investment Conference, which is being held virtually on September 22, 2026. Management is scheduled to participate in 1×1 meetings only, with no formal presentation session. The Sidoti Small Cap Conference, which is being held virtually from September 23-24, 2026. Management is scheduled to participate in 1×1 meetings only on Wednesday, September 23rd, with no formal presentation session. Live audio webcasts of the fireside chats will be accessible under the “Events” section of Merit’s investor relations website at Investor Events and Presentations – Merit Medical. Replays of the fireside chats will be available on this same website for approximately 90 days.ABOUT MERIT MEDICAL Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide. CONTACTS PR/Media Inquiries Sarah ComstockMerit Medical +1-801-432-2864 | sarah.comstock@merit.com Investor Inquiries Mike Piccinino, CFA, IRC ICR Healthcare +1-443-213-0509 | mike.piccinino@icrhealthcare.com
Medtronic Endurant™ stent graft system first and only to receive CE-mark for updated rupture labeling
Following recent U.S. Food and Drug Administration (FDA) labeling approval, European label milestone reinforces Medtronic leadership in advancing aortic care based on clinical evidence supporting the treatment of ruptured abdominal aortic aneurysms (rAAA). Cardiovascular Diagnostics and Services Europe, Middle East & Africa Medtronic plc, a global leader in healthcare technology, […]
SinglePass Device Achieves 100% Technical Success and Zero Clinically Significant Bleeding Events in Multicenter Study Published in the Journal of Vascular and Interventional Radiology
LAKE FOREST, Calif.–(BUSINESS WIRE)–SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy
InnovHeart Announces First U.S. Saturn Transseptal TMVR System Implant, Reaching 15 Patients Globally
NEWTON, Mass. and MILAN, Sept. 3, 2026 /PRNewswire/ — InnovHeart, a medical device company developing the Saturn Transseptal Transcatheter Mitral Valve Replacement (TMVR) System, today announces the successful implantation of the first U.S. patient with the Saturn system as part of the…
Philips advances women’s health ultrasound with new single-transducer solution
Philips eV14-2v transducer
Philips eV14-2v transvaginal transducer, designed to support a broad range of gynecology and early obstetrics exams.
Clinician holding Philips eV14-2v transducer
A clinician holds the Philips eV14-2v transvaginal transducer.
Patient consultation with Philips Alturion ultrasound
A clinician consults with a patient alongside the Philips Alturion ultrasound system and eV14-2v transducer during a women’s health appointment.
September 3, 2026 FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer. The new transducer will be showcased at the 36th International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) World Congress. Across obstetrics and gynecology, clinicians care for women with diverse clinical needs, from routine gynecologic exams to early pregnancy assessments and more complex cases. Achieving the desired balance of penetration and image resolution may require switching between transducers, which can interrupt workflow and extend exam times. The eV14-2v is designed to address these challenges by providing enhanced penetration, improved resolution, and a wider field of view in a lightweight, ergonomic design. The transducer delivers a 41.7% increase in penetration, a 10% increase in 2D resolution, a 15.8% improvement in field of view, and a 22% lighter design, supporting imaging across routine and complex gynecology and early obstetrics exams [1]. “Advancing women’s health is a priority for Philips ultrasound, and we are committed to developing innovations that make women’s healthcare more accessible and more comfortable for patients,” said Ajay Gannerkote, Ultrasound Business Leader at Philips. “At Philips, we’re focused on bringing together high-quality imaging, intelligent workflows and connected capabilities to simplify the ultrasound experience for clinicians and patients. The eV14-2v transducer reflects that approach, giving clinicians greater versatility in a single transducer and helping support high-quality care for women.” Built specifically for gynecology and obstetrics imaging, the eV14-2v leverages PureWave crystal technology, first introduced by Philips, and features a lightweight ergonomic design that supports user comfort during exams. This gives clinicians detailed visualization of anatomy relevant to evaluating infertility and pelvic pain associated with conditions such as endometriosis and fibroids. Philips technology, including 2D and color resolution, supports the detection of fetal abnormalities, with the ability to delineate the cardiac chambers in a fetus as early as 13 weeks when the heart is the size of a single corn kernel [2]. “Reducing transducer changes during exams has a meaningful impact, not just on efficiency, but on the patient experience as well,” said Dr. Michael S. Ruma, MD, MPH, Perinatal Associates of New Mexico. “With the eV14-2v, we’re able to complete more exams with a single transducer while maintaining excellent image quality, which helps streamline our workflow and improve patient comfort.” The eV14-2v transducer can be used with Philips Collaboration Live, supporting real-time remote consultation during ultrasound exams. Clinicians can view live imaging, provide guidance during exams, and consult with care teams without requiring patient travel. This approach can help expand access to specialty care in underserved communities while supporting more efficient care delivery. In addition to the eV14-2v transducer, attendees at ISUOG 2026 will have the opportunity to experience Philips’ latest women’s healthcare ultrasound innovations firsthand, including the newly launched Alturion ultrasound system, EPIQ Elite, Lumify, and Flash with Collaboration Live, and learn more about the company’s ongoing efforts to advance ultrasound solutions for women worldwide. For further information on the eV14-2v transducer, please visit: Philips – eV14-2v Transducer FUS0929 – Philips. [1] Compared to the 3D9-3v transducer[2] Video image on file For further information, please contact: Jayme Maniatis Philips Global External Relations Tel.: 617-894-8368 E-mail: jayme.maniatis@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
Philips eV14-2v transducer
Clinician holding Philips eV14-2v transducer
Patient consultation with Philips Alturion ultrasound
Heartvue.ai and Innolitics Achieve FDA 510(k) Clearance for Heartvue.Proton, an AI-Powered Cardiac MRI Analysis Platform
BRENTWOOD, Tenn. & AUSTIN, Texas–(BUSINESS WIRE)–Heartvue.ai, a cardiac imaging AI company founded by cardiologists, and Innolitics, a medical device software and regulatory consultancy, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance (K260811) for Heartvue.Proton, Heartvue’s machine learning–powered software for viewing, post-processing, and quantitative evaluation of cardiovascular magnetic resonance (MR) images. Innolitics guided Heartvue from initia
Elucid Raises $55 Million in Oversubscribed Series D Financing
Funding will accelerate commercialization of Elucid’s AI-powered cardiovascular imaging platform and expand strategic partnerships with leading medical technology companies BOSTON — Sept. 2, 2026 — Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, today announced the raise of $55 million […]
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today announced findings from a study of 1,385 patients with suspected coronary artery disease (CAD) presented at the European Society of Cardiology (ESC) Congress 2026 in Munich. The study, titled “Temporal associations of coronary plaque burden and myocardial perfusion with clinical outcomes,” was led by Jorge Dahdal, MD, of Clínica Alemana de Santiago, Chile, and Amsterdam UMC, the Netherlands, and presen
AHA/ASA 2026 Guideline Now Recognizes Pharyngeal Electrical Stimulation for Stroke Rehabilitation
Newly updated recommendation extends consideration of PES into stroke rehabilitation and recovery, further advancing Phagenesis’ mission to restore swallowing function, independence and dignity after stroke NASHVILLE, Tenn., Sept. 2, 2026 /PRNewswire/ — A new 2026 guideline from the…



